PPGN POLYPEPTIDE GROUP AG

Doubling of production capacity at the manufacturing site in Malmö

PolyPeptide Group / Key word(s): Expansion
Doubling of production capacity at the manufacturing site in Malmö

08.01.2025 / 07:00 CET/CEST


Media release

Doubling of production capacity at the manufacturing site in Malmö

Baar, 8 January 2025 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, announces the planned doubling of solid-phase peptide synthesis (SPPS) capacity at its manufacturing site in Malmö, Sweden.

The construction work is already underway, along with the supporting infrastructure, including a tank farm. PolyPeptide uses its proprietary manufacturing technology with an integrated engineering design and advanced automation and process control to ensure high productivity, safety, and sustainability. A modular approach is intended to accelerate time to market, while enhancing flexibility to ensure high utilization. As part of its mid-term outlook communicated on 13 August 2024, PolyPeptide plans to invest around EUR 100 million at the site and to create approximately100 permanent new positions.

The additional production capacity will mainly serve to fulfill one of the large commercial agreements previously communicated by PolyPeptide. It relates to one of the growth initiatives reflected in the mid-term outlook, whereby PolyPeptide targets to double 2023 revenue by 2028 and to deploy capital expenditures of 15% to 20% of revenue to ensure capacity, also beyond 2028.

Juan José González, CEO of PolyPeptide: “The large-scale capacity expansion in Malmö allows us to further deepen the long-standing collaboration with an important GLP-1 customer. We are making good progress with the implementation of our growth strategy to meet our mid-term targets, benefiting from balanced, supportive partnerships with customers.”

 

Contact

PolyPeptide Group AG

Michael Stäheli

Head of Investor Relations & Corporate Communications

T:

 

About PolyPeptide

PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a focused Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide offers products and services from pre-clinical through to commercial stages, including generics. Its active custom projects pipeline reflects the opportunities from novel drug therapies in development to fight both widespread and rare diseases. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange.

For more information, please visit .  

@PolyPeptide – follow us on

 

Disclaimer

This media release has been prepared by PolyPeptide Group AG and contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual developments to differ materially from those expressed or implied in this release. In particular, the statements related to the guidance for 2024, and mid-term outlook constitute forward-looking statements and are not guarantees of future financial performance. The Group’s actual results of operations could deviate materially from those set forth in the guidance for 2024 and mid-term outlook. As such, investors should not place undue reliance on the statements related to the guidance for 2024 and mid-term outlook. PolyPeptide Group AG is providing the information in this release as of this date and, except as required by applicable laws or regulations, does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.

 

 



End of Media Release


Language: English
Company: PolyPeptide Group
Neuhofstrasse 24
6340 Baar
Switzerland
Phone:
E-mail:
Internet:
ISIN: CH1110760852
Valor: 111076085
Listed: SIX Swiss Exchange
EQS News ID: 2063079

 
End of News EQS News Service

2063079  08.01.2025 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2063079&application_name=news&site_id=research_pool~~~9efe1c65-8ece-4ff7-9608-f21c8e0a38a3
EN
08/01/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on POLYPEPTIDE GROUP AG

 PRESS RELEASE

PolyPeptide publiziert Einladung zur ordentlichen Generalversammlung 2...

PolyPeptide Group / Schlagwort(e): Generalversammlung PolyPeptide publiziert Einladung zur ordentlichen Generalversammlung 2025 18.03.2025 / 07:00 CET/CEST Medienmitteilung PolyPeptide publiziert Einladung zur ordentlichen Generalversammlung 2025 Baar, 18. März 2025 – PolyPeptide Group AG (SIX: PPGN), eine spezialisierte globale CDMO für peptidbasierte aktive pharmazeutische Wirkstoffe, hat heute die Einladung zur vierten ordentlichen Generalversammlung publiziert, die am 9. April 2025 in der Chollerhalle in Zug stattfinden wird. An PolyPeptide Group AG’s (die "Gesellsch...

 PRESS RELEASE

PolyPeptide publishes invitation to the annual General Meeting 2025

PolyPeptide Group / Key word(s): AGMEGM PolyPeptide publishes invitation to the annual General Meeting 2025 18.03.2025 / 07:00 CET/CEST Media release PolyPeptide publishes invitation to the annual General Meeting 2025 Baar, 18 March 2025 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, published today the invitation to the fourth annual General Meeting, which will take place on 9 April 2025 at the Chollerhalle in Zug. At PolyPeptide Group AG’s (the “Company”) fourth annual General Meeting, which will take place...

 PRESS RELEASE

Doubling of production capacity at the manufacturing site in Malmö

PolyPeptide Group / Key word(s): Expansion Doubling of production capacity at the manufacturing site in Malmö 08.01.2025 / 07:00 CET/CEST Media release Doubling of production capacity at the manufacturing site in Malmö Baar, 8 January 2025 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, announces the planned doubling of solid-phase peptide synthesis (SPPS) capacity at its manufacturing site in Malmö, Sweden. The construction work is already underway, along with the supporting infrastructure, including a tan...

 PRESS RELEASE

Verdoppelung der Produktionskapazität am Standort Malmö

PolyPeptide Group / Schlagwort(e): Expansion Verdoppelung der Produktionskapazität am Standort Malmö 08.01.2025 / 07:00 CET/CEST Medienmitteilung Verdoppelung der Produktionskapazität am Standort Malmö Baar, 8. Januar 2025 – PolyPeptide Group AG (SIX: PPGN), ein spezialisierter globaler CDMO für peptidbasierte aktive pharmazeutische Wirkstoffe, kündigt die geplante Verdoppelung der Kapazität für die Festphasenpeptidsynthese (SPPS) am Produktionsstandort Malmö, Schweden, an. Die Konstruktionsarbeiten sind bereits im Gang, zusammen mit der unterstützenden Infrastruktur, in...

 PRESS RELEASE

Large-scale SPPS capacity in Braine-l’Alleud starts production

PolyPeptide Group / Key word(s): Miscellaneous Large-scale SPPS capacity in Braine-l’Alleud starts production 16.12.2024 / 07:00 CET/CEST Media release Large-scale SPPS capacity in Braine-l’Alleud starts production Baar, 16 December 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, announces the start of production with the new large-scale SPPS capacity at its manufacturing site in Braine-l’Alleud, Belgium. Following the completion of construction and thorough testing, PolyPeptide commissioned its new solid...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch